Gene Editing as a Potential One-Time Treatment for High Cholesterol
Overview
Early-stage gene-editing therapies targeting ANGPTL3 and PCSK9 genes show promise in significantly lowering LDL cholesterol and triglycerides with a single treatment. These novel approaches could revolutionize heart disease prevention by potentially eliminating the need for lifelong medication.
Background
High LDL cholesterol is a major contributor to heart attacks and strokes, the leading causes of death worldwide. Current treatments like statins require lifelong adherence and may have side effects, leading to poor compliance. Genetic factors influence cholesterol levels, with some individuals naturally having mutations that reduce LDL cholesterol and triglycerides. Gene-editing technologies such as CRISPR offer a new avenue to mimic these beneficial mutations by permanently switching off specific genes involved in cholesterol regulation.
Data Highlights
Study
Gene Targeted
Number of Participants
LDL Reduction
Triglyceride Reduction
CRISPR Therapeutics
ANGPTL3
15 adults
~50% (highest dose)
~50% (highest dose)
Verve Therapeutics (Eli Lilly)
PCSK9
Small study
Similar LDL reduction (~50%)
Not specified
Key Findings
Single infusions of CRISPR-based therapies targeting ANGPTL3 or PCSK9 genes can reduce LDL cholesterol by approximately 50% within two weeks.
Triglyceride levels also dropped by about half in the ANGPTL3 gene-editing study.
Gene editing effects appear durable, with some participants maintaining lowered cholesterol for up to two years.
Gene editing is permanent, as edited liver cells and their progeny carry the altered genes potentially for a lifetime.
Long-term safety and off-target effects remain unknown, necessitating further larger and longer studies.
Current trials focus on individuals at very high risk for cardiovascular disease due to safety considerations.
Clinical Implications
Gene-editing therapies could transform cholesterol management by providing a one-time, durable treatment alternative to daily medications. However, clinicians should remain cautious until long-term safety and efficacy data are available. Meanwhile, established lifestyle modifications and pharmacologic treatments remain essential for cardiovascular risk reduction.
Conclusion
Gene editing targeting cholesterol-regulating genes holds significant promise as a potential single-treatment solution for high cholesterol, but further research is needed to confirm long-term safety and effectiveness before widespread clinical use.
References
AP Health and Science Department 2023 -- Is gene editing the potential single-treatment solution for high cholesterol?
A Keck Medicine of USC cardiothoracic surgeon explains why epicardial ablation may be the right treatment for some patients with longstanding persistent AFib.
